Positive News SentimentPositive NewsNASDAQ:HLVX HilleVax (HLVX) Stock Price, News & Analysis $2.15 +0.01 (+0.47%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.14 0.00 (-0.23%) As of 07/25/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About HilleVax Stock (NASDAQ:HLVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HilleVax alerts:Sign Up Key Stats Today's Range$2.09▼$2.1650-Day Range$1.83▼$2.1752-Week Range$1.34▼$2.17Volume162,970 shsAverage Volume356,537 shsMarket Capitalization$107.80 millionP/E RatioN/ADividend YieldN/APrice Target$2.00Consensus RatingHold Company Overview HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts. Read More HilleVax Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreHLVX MarketRank™: HilleVax scored higher than 40% of companies evaluated by MarketBeat, and ranked 710th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingHilleVax has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHilleVax has received no research coverage in the past 90 days.Read more about HilleVax's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for HilleVax are expected to grow in the coming year, from ($2.64) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of HilleVax is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HilleVax is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHilleVax has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about HilleVax's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.33% of the float of HilleVax has been sold short.Short Interest Ratio / Days to CoverHilleVax has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HilleVax has recently decreased by 53.28%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHilleVax does not currently pay a dividend.Dividend GrowthHilleVax does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.33% of the float of HilleVax has been sold short.Short Interest Ratio / Days to CoverHilleVax has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HilleVax has recently decreased by 53.28%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News SentimentN/A News SentimentHilleVax has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for HilleVax this week, compared to 1 article on an average week. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, HilleVax insiders have not sold or bought any company stock.Percentage Held by Insiders24.90% of the stock of HilleVax is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.42% of the stock of HilleVax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about HilleVax's insider trading history. Receive HLVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter. Email Address HLVX Stock News HeadlinesHilleVax (HLVX) Upgraded to Strong Buy: What Does It Mean for ... - NasdaqJuly 13, 2025 | nasdaq.comIs HilleVax (NASDAQ:HLVX) In A Good Position To Deliver On Growth Plans?July 3, 2025 | finance.yahoo.comCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. July 26 at 2:00 AM | Timothy Sykes (Ad)HilleVax, Inc. (NASDAQ:HLVX) is largely controlled by institutional shareholders who own 51% of the companyMay 22, 2025 | finance.yahoo.comHilleVax, Inc.: HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company ProgressMay 9, 2025 | finanznachrichten.deHilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company ProgressMay 8, 2025 | globenewswire.comHilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company ProgressMarch 28, 2025 | globenewswire.comHillevax CEO Robert Hershberg sells $48,661 in stockFebruary 12, 2025 | msn.comSee More Headlines HLVX Stock Analysis - Frequently Asked Questions How have HLVX shares performed this year? HilleVax's stock was trading at $2.07 at the start of the year. Since then, HLVX shares have increased by 3.9% and is now trading at $2.15. How were HilleVax's earnings last quarter? HilleVax, Inc. (NASDAQ:HLVX) released its quarterly earnings data on Thursday, May, 8th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.25. When did HilleVax IPO? HilleVax (HLVX) raised $200 million in an IPO on Friday, April 29th 2022. The company issued 11,765,000 shares at $16.00-$18.00 per share. How do I buy shares of HilleVax? Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HilleVax own? Based on aggregate information from My MarketBeat watchlists, some other companies that HilleVax investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Home Depot (HD). Company Calendar Last Earnings5/08/2025Today7/26/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HLVX CIK1888012 Webwww.hillevax.com Phone617-213-5054FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for HilleVax$2.00 High Price Target$2.00 Low Price Target$2.00 Potential Upside/Downside-7.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($2.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$147.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-51.86% Return on Assets-41.45% Debt Debt-to-Equity RatioN/A Current Ratio25.32 Quick Ratio25.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.10 per share Price / Book0.69Miscellaneous Outstanding Shares50,140,000Free Float37,656,000Market Cap$107.80 million OptionableNot Optionable Beta0.76 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:HLVX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Goldco Precious Metals | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HilleVax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HilleVax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.